Press Releases Events & Presentations Press Releases Year None2022202120202019201820172016201520142013201220112010 Jun 22, 2022 Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022 View HTML PDF Version Jun 21, 2022 Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022 View HTML PDF Version Jun 08, 2022 Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022 View HTML PDF Version Jun 06, 2022 Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection View HTML PDF Version Jun 03, 2022 Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version May 12, 2022 Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights View HTML PDF Version Apr 01, 2022 Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Mar 21, 2022 Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022 View HTML PDF Version Mar 10, 2022 Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights View HTML PDF Version Feb 09, 2022 Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds Search Investors
Press Releases Year None2022202120202019201820172016201520142013201220112010 Jun 22, 2022 Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022 View HTML PDF Version Jun 21, 2022 Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022 View HTML PDF Version Jun 08, 2022 Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022 View HTML PDF Version Jun 06, 2022 Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection View HTML PDF Version Jun 03, 2022 Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version May 12, 2022 Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights View HTML PDF Version Apr 01, 2022 Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Mar 21, 2022 Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022 View HTML PDF Version Mar 10, 2022 Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights View HTML PDF Version Feb 09, 2022 Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last »
